Issue Information
28 February 2019
28 February 2019
28 February 2019
28 February 2019
Jaclyn LoPiccolo, Michael I. Brener, Kiyoko Oshima, Evan J. Lipson, James P. Hamilton – 28 February 2019
28 February 2019
28 February 2019
Kristopher P. Croome, David D. Lee, C. Burcin Taner – 28 February 2019 – The frequency at which steatotic deceased donor liver grafts are encountered will likely continue to increase. Utilization of liver grafts with moderate‐to‐severe steatosis for liver transplantation (LT) has been previously shown to be associated with increased rates of primary nonfunction and decreased recipient survival. In order to better inform clinical decision making and guide future research, critical evaluation of the literature on donor liver steatosis and posttransplantation outcome is needed.
Steven M. Kawut, Susan S. Ellenberg, Michael J. Krowka, David Goldberg, Hugo Vargas, David Koch, Tiffany Sharkoski, Nadine Al‐Naamani, Alyson Fox, Robert Brown, Joshua Levitsky, Jae K. Oh, Grace Lin, Nianfu Song, Carl Mottram, Margaret F. Doyle, David E. Kaplan, Samir Gupta, Michael B. Fallon – 28 February 2019 – The tyrosine kinase inhibitor sorafenib improves hepatopulmonary syndrome (HPS) in an experimental model. However, the efficacy and adverse effect profile in patients with HPS are unknown.
Yuri L. Boteon, Joseph Attard, Amanda P. C. S. Boteon, Lorraine Wallace, Gary Reynolds, Stefan Hubscher, Darius F. Mirza, Hynek Mergental, Ricky H. Bhogal, Simon C. Afford – 28 February 2019 – Strategies to increase the use of steatotic donor livers are required to tackle the mortality on the transplant waiting list. We aimed to test the efficacy of pharmacological enhancement of the lipid metabolism of human livers during ex situ normothermic machine perfusion to promote defatting and improve the functional recovery of the organs.
27 February 2019